Shopping Cart
Remove All
Your shopping cart is currently empty
NRX-252114 (NRX252114) induces degradation of mutant β-catenin NRX-252114 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP, and is able to enhance the binding of pSer33/S37A β-catenin to β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. Kd is 0.4 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $196 | In Stock | In Stock | |
| 5 mg | $497 | In Stock | In Stock | |
| 10 mg | $723 | In Stock | In Stock | |
| 25 mg | $1,130 | In Stock | In Stock | |
| 50 mg | $1,520 | In Stock | In Stock | |
| 100 mg | $1,980 | - | In Stock | |
| 500 mg | $3,970 | - | In Stock |
| Description | NRX-252114 (NRX252114) induces degradation of mutant β-catenin NRX-252114 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP, and is able to enhance the binding of pSer33/S37A β-catenin to β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. Kd is 0.4 nM. |
| Targets&IC50 | β-catenin-β-TrCP:0.4 nM(Kd), β-catenin-β-TrCP:6.5 nM(EC50) |
| Synonyms | NRX252114, NRX 252114 |
| Molecular Weight | 510.32 |
| Formula | C22H12Cl2F3N3O2S |
| Cas No. | 2763260-39-3 |
| Smiles | S(C1=C(C(=O)N2CC=3C(C2)=CC=CC3C#N)C(=O)NC(C(F)(F)F)=C1)C4=C(Cl)C=CC=C4Cl |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (97.98 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.